Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
NRIX - Nurix Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$32.20
DETAILS
HIGH:
$36.00
LOW:
$28.00
MEDIAN:
$32.00
CONSENSUS:
$32.20
UPSIDE:
84.00%
Stock News
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers, both single- and multiple-ascending-dose oral dosing of bexobrutideg led to rapid and robust BTK degradation in blood and skin Phase 1 studies support continued exploration of new tablet formulation in inflammation and immunology indications BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the presentation of new preclinical and Phase 1 translational data highlighting the potential of bexobrutideg (NX-5948), the company's wholly owned Bruton's tyrosine kinase (BTK) degrader, in chronic spontaneous urticaria (CSU).
Nurix Therapeutics to Participate in Upcoming Investor Conferences
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences:
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that an abstract highlighting updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy has been accepted for oral presentation at the 31st Congress of the European Hematology Association (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden.
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000
Nurix Therapeutics, a biotech innovator in targeted cancer therapies, reported a notable insider sale amid strong one-year stock gains.
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach Featured AACR Advances session underscores Nurix's scientific leadership in targeted protein degradation and induced proximity pharmacology BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation therapies, today announced new preclinical data from multiple oncology programs at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 85.8% in Nurix Therapeutics (NRIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide
Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg for relapsed/refractory CLL in pivotal phase 2 trials. Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. Expansion efforts include higher-dose bexobrutideg for earlier CLL lines, an oral formulation for immunology, and the dual BTK/IKZF degrader zelebrudomide for B-cell malignancies.
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $0.67 per share a year ago.
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)
Nurix Therapeutics to Participate in Upcoming Investor Conference
BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur Sands, M.D.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation
Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that two oral presentations and three poster presentations highlighting the breadth of its research pipeline and scientific leadership will be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting, to be held April 17-22, 2026, in San Diego, California.
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
Redmile Group increased its Nurix Therapeutics holding by 4,415,514 shares; the estimated trade value was $63.43 million based on quarterly average pricing. Meanwhile, the quarter-end position value rose by $119.55 million, reflecting the combined impact of share purchases and Nurix Therapeutics' price movement.
Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight
Executives from Nurix Therapeutics (NASDAQ: NRIX) used a recent discussion on the company's immunology and inflammation (I&I) efforts to outline why the firm believes targeted protein degradation could offer advantages over conventional small-molecule inhibition in inflammatory diseases. While Nurix is often associated with its oncology programs, company leadership argued its I&I pipeline-centered on BTK, IRAK4, and
Nurix Therapeutics (NASDAQ:NRIX) CFO Sells $60,772.60 in Stock
Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report) CFO Houte Hans Van sold 3,661 shares of the stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $60,772.60. Following the completion of the transaction, the chief financial officer owned 45,427 shares of
Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $81,257.00 in Stock
Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report) insider Gwenn Hansen sold 4,895 shares of the stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $81,257.00. Following the completion of the transaction, the insider owned 83,672 shares of the
Price Targets
Nurix Therapeutics price target lowered to $28 from $29 at Wells Fargo
$28.00
(was $16.24)
Wells Fargo
Nurix Therapeutics price target raised to $35 from $33 at Stifel
$35.00
(was $18.55)
Stifel Nicolaus
Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo
$29.00
(was $17.87)
Derek Archila
·
Wells Fargo
Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright
$32.00
(was $17.87)
H.C. Wainwright
Nurix Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
$36.00
(was $18.49)
Morgan Stanley
Nurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright
$31.00
(was $19.55)
Robert Burns
·
H.C. Wainwright
Nurix Therapeutics price target raised to $30 from $27 at BTIG
$30.00
(was $21.47)
BTIG
Nurix Therapeutics assumed with a Buy at Truist
$30.00
(was $17.18)
Truist Financial
Nurix Therapeutics price target lowered to $28 from $33 at H.C. Wainwright
$28.00
(was $11.93)
H.C. Wainwright
Nurix Therapeutics price target lowered to $27 from $35 at BTIG
$27.00
(was $10.63)
BTIG
Nurix Therapeutics price target lowered to $21 from $22 at Wells Fargo
$21.00
(was $10.47)
Wells Fargo
Nurix Therapeutics price target raised to $29 from $28 at RBC Capital
$29.00
(was $10.63)
Gregory Renza
·
RBC Capital
Nurix Therapeutics price target lowered to $33 from $34 at H.C. Wainwright
$33.00
(was $9.72)
H.C. Wainwright
Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo
$22.00
(was $9.76)
Wells Fargo
Nurix Therapeutics price target lowered to $33 from $35 at Stifel
$33.00
(was $9.76)
Stifel Nicolaus
Nurix Therapeutics price target lowered to $28 from $30 at Oppenheimer
$28.00
(was $10.86)
Matthew Biegler
·
Oppenheimer
Nurix Therapeutics price target lowered to $32 from $35 at Piper Sandler
$32.00
(was $10.86)
Piper Sandler
Nurix Therapeutics price target lowered to $16 from $17 at Morgan Stanley
$16.00
(was $12.69)
Terence Flynn
·
Morgan Stanley
Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer
$30.00
(was $12.67)
Matthew Biegler
·
Oppenheimer
Nurix Therapeutics initiated with a Market Perform at Leerink
$16.00
(was $13.93)
Leerink Partners